Inventor · disambiguated record
Kathrin Tissot
Also filed as: TISSOT KATHRIN
11 granted patents·10 pending applications·89 citations·filing 2003–2024
90Inventor score
Top patents by PatentIndex Score
21 records- 0195US9828420B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2016·Granted Nov 28, 2017·14 cites·22 claims
- 0292US10202445B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2017·Granted Feb 12, 2019·7 cites·13 claims
- 0391US10131708B2Methods of treating Alzheimer's diseaseUNIV OF ZUERICH·Filed 2017·Granted Nov 20, 2018·12 cites·88 claims
- 0491US8906367B2Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2008·Granted Dec 9, 2014·29 cites·21 claims
- 0589US9670272B2Method of providing disease-specific binding molecules and targetsUNIV OF ZÜRICH·Filed 2012·Granted Jun 6, 2017·14 cites·10 claims
- 0688US12171839B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2022·Granted Dec 24, 2024·1 cites·11 claims
- 0779US2025064964A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0878US8853362B2Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying sameTISSOT KATHRIN·Filed 2003·Granted Oct 7, 2014·12 cites·9 claims
- 0977US2022403011A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2022·Application pending·0 cites
- 1071US2020165322A1Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying sameNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1170US2019153082A1Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2018·Application pending·0 cites
- 1266US2019263896A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2018·Application pending·0 cites
- 1365US2015147343A1Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2014·Application pending·0 cites
- 1464US2013266585A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 1564US2013266586A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 1664US2013266514A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 1763US10570190B2Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying sameESBATECH ALCON BIOMED RES UNIT·Filed 2018·Granted Feb 25, 2020·0 cites·1 claims
- 1862US9518108B2Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying sameESBATECH ALCON BIOMED RES UNIT·Filed 2014·Granted Dec 13, 2016·0 cites·10 claims
- 1958US10125186B2Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying sameESBATECH ALCON BIOMED RES UNIT·Filed 2016·Granted Nov 13, 2018·0 cites·10 claims
- 2057US11357864B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 2150US2021228731A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →